查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1660964

RNA 干扰药物传递​​市场报告（按应用、技术和地区）2025 年至 2033 年

RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球 RNA 干扰 (RNAi) 药物输送市场规模达到 998 亿美元。 展望未来， IMARC Group预计到 2033 年市场规模将达到 4,661 亿美元，2025-2033 年期间的成长率 (CAGR) 为 17.75%。

核糖核酸干扰（RNAi）药物传递是一种监测基因表现或突变的治疗方案。 RNAi 药物输送通常透过静脉、皮内和腹膜内注射和局部输送方法进行。它涉及奈米颗粒、肺部、核酸和适体药物传输技术。这些技术也用于分析真核生物的基因功能和开发治疗性基因沉默解决方案。因此，RNAi药物传递广泛用于治疗传染病、慢性代谢紊乱、心血管疾病、神经疾病、泌尿疾病、肿瘤疾病和眼科疾病。

全球癌症和心血管疾病（CVD）等慢性疾病和遗传疾病的发生率不断上升，这是推动市场成长的关键因素之一。此外，老年人口的增加使人们更容易患上此类疾病，这也推动了市场的成长。同时，随着冠状病毒病（COVID-19）继续在全球蔓延，对 RNAi 药物传递技术的需求显着增加。标靶递送方法，例如适体药物递送系统，在抗病毒药物的给药方面获得了巨大的吸引力，因为它们是由可以抑制病毒抗原表达的小干扰 RNA (siRNA) 诱导的。此外，各种技术进步，如创新合成运载载体和生物载体的开发，预计将推动市场成长。奈米载体，包括 siRNA 或微小 RNA（miRNA），对于开发个人化药物和识别改变的细胞分子和代谢物至关重要。其他因素，包括奈米技术和分子诊断领域的广泛研究和开发 (R&D) 活动，以及医疗保健基础设施的全面改善，预计将进一步推动市场发展。

本报告回答的关键问题：

  • 全球 RNA 干扰（RNAi）药物输送市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对全球 RNA 干扰 (RNAi) 药物输送市场有何影响？
  • 主要的区域市场有哪些？
  • 根据应用，市场区隔是怎样的？
  • 基于科技的市场分化是怎样的？
  • 该产业的价值链分为哪些阶段？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球 RNA 干扰（RNAi）药物输送市场的结构是怎样的？
  • 产业的竞争程度如何？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球 RNA 干扰 (RNAi) 药物输送市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第六章：市场区隔：依应用

  • 传染病
    • 市场趋势
    • 市场预测
  • 心臟病学
    • 市场趋势
    • 市场预测
  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 神经病学
    • 市场趋势
    • 市场预测
  • 眼科
    • 市场趋势
    • 市场预测
  • 泌尿科
    • 市场趋势
    • 市场预测
  • 代谢紊乱
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第七章：市场区隔：依技术

  • 奈米颗粒药物输送
    • 市场趋势
    • 市场预测
  • 肺部药物输送
    • 市场趋势
    • 市场预测
  • 核酸药物输送
    • 市场趋势
    • 市场预测
  • 适体药物递送
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场区隔：依国家
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Alnylam Pharmaceuticals Inc.
    • Arrowhead Pharmaceuticals Inc.
    • CureVac AG
    • Dicerna Pharmaceuticals Inc.
    • Gradalis Inc.
    • Ionis Pharmaceuticals Inc
    • Merck & Co. Inc.
    • Moderna Inc.
    • Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
    • Silence Therapeutics Plc
    • Sirnaomics Inc.
Product Code: SR112025A2758

The global RNA interference (RNAi) drug delivery market size reached USD 99.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 466.1 Billion by 2033, exhibiting a growth rate (CAGR) of 17.75% during 2025-2033.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Application:

  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others

Breakup by Technology:

  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc, and Sirnaomics Inc.

Key Questions Answered in This Report:

  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Infectious Disease
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oncology
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Neurology
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Ophthalmology
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Urology
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Metabolic Disorders
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Nanoparticle Drug Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Pulmonary Drug Delivery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Nucleic Acid Drug Delivery
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Aptamer Drug Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Alnylam Pharmaceuticals Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arrowhead Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 CureVac AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Dicerna Pharmaceuticals Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Gradalis Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Ionis Pharmaceuticals Inc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck & Co. Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Moderna Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Silence Therapeutics Plc
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
    • 13.3.11 Sirnaomics Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
  • Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2024
  • Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2024
  • Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
  • Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
  • Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
  • Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players